Cullinan Therapeutics: Worthy Of A Small Position

Group 1 - Cullinan Therapeutics, Inc. (NASDAQ: CGEM) shares have declined approximately 70% since May 2024 due to a lack of data regarding its off-the-shelf CD19xCD3 T cell engager CLN-978 [2] - The company is focused on autoimmune and oncology therapies, with the CLN-978 therapy being particularly anticipated by investors [2] - The Biotech Forum offers a model portfolio featuring 12-20 high upside biotech stocks, along with live discussions and weekly updates [2] Group 2 - The article emphasizes the importance of market commentary and portfolio updates provided by The Biotech Forum on a weekly basis [2] - Analyst disclosures indicate a beneficial long position in shares of AMGN and CGEM, highlighting the analyst's personal investment interests [3] - Seeking Alpha clarifies that past performance does not guarantee future results and that the views expressed may not reflect the platform's overall stance [4]